C2N Diagnostics, LLC is a privately held protein diagnostic and therapeutic discovery company targeting progressive neurodegeneration. We formed in late 2007 by scientific co-founders Drs. David Holtzman and Randall Bateman of Washington University School of Medicine in St. Louis, and LifeTech Research, a Maryland-based technology research and commercialization firm (www.lifetechresearch.com). We reside at the Center for Emerging Technologies in St. Louis.

Our therapeutic discovery efforts are focused around mechanism-based approaches to prevent or stop the progression of human neurological disorders.

Our diagnostic efforts are leading ways to understand molecular mechanisms of brain diseases, track early progression, and measure the biologic activity of emerging therapies. By measuring the concentration and metabolism of CNS-derived biomolecules using sensitive stable isotope labeling, we provide novel insights into the normal and abnormal workings of the brain.